Sinclair Research Blog

Sinclair Research Appoints Scott Boley as Vice President of Toxicology


by Sinclair Research

Columbia, MO, July 25, 2018 (Business Wire) — Sinclair Research, one of the nation’s leading providers of nonclinical services, has named Scott E. Boley, PhD, DABT, as vice president of toxicology. In this newly created role, he will have overall responsibility for driving the growth of Sinclair’s toxicology efforts and fostering relationships with new and current customers.

Dr. Boley became a board-certified toxicologist in 2003, and has extensive expertise in drug development as well as the regulatory expectations for a variety of test article types and indications. He will be applying his breadth of experience to benefit Sinclair customers.

“Scott is an experienced toxicologist who is well-known in the industry,” said Guy Bouchard, DVM, president of Sinclair Research Center. “He is an expert in compound safety assessment with a deep regulatory understanding. Scott has advised sponsors with compound safety regulatory needs for the last 13 years and managed toxicology programs for 17 years. He will be an asset to our clients and their consultants.”

Scott joins Sinclair Research from MPI Research in Mattawan, Mich. He joined MPI in 2005 as a study director in general toxicology and was promoted to senior director of general toxicology and infusion. For the last four years, he served as senior scientific advisor working with the business development arm of MPI, assisting sponsors in evaluating which nonclinical studies they needed for their test article. Prior to MPI, Boley worked at Eli Lilly and Company where he was the toxicology lead on development teams for novel therapeutics designing, implementing, and overseeing nonclinical safety studies.

About Sinclair Research

Sinclair Research Center, a preclinical contract research organization (CRO) established in 1964, offers animal efficacy models, IND enabling toxicology services and research capabilities to animal health and medical device companies. Our clients include large, mid-tier, small and startup companies in both human and animal health markets. With more than 50 years’ experience, Sinclair is the undisputed expert in all breeds of miniature swine. In addition, we manage many standing animal colony models including diabetes, wound healing, irritable bowel disease and general PK, and we have developed and maintain our own unique research breed of mini-swine, “The Sinclair Pig.”